At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
CRx-102 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA
In Brief
A Phase 2 clinical trial evaluating CRx-102, Placebo, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 59 participants.
Detailed Summary
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid Arthritis. This Phase II, 6-week blinded study was planned for 60 subjects with moderate to severe rheumatoid arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2004
Primary CompletionSep 2006
Study CompletionNov 2006
First PostedSep 2008
TodayJul 2026
First PostedSep 5, 2008
Enrollment StartNov 1, 2004
Primary CompletionSep 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.8 years ago
Interventions
CRx-102drug
Placebodrug
DMARD Therapydrug
DMARD therapy can include methotrexate or other DMARD therapy